ApoA-1, human recombinant protein
Apolipoprotein A-I
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P02647 |
|---|---|
| Calculated MW | 28.2 kDa |
| Gene ID | 335 |
|---|---|
| Gene Symbol | ApoA1 |
| Other Names | APOA1, MGC117399, Apoa1, Alp-1, Apoa-1, Brp-14, Ltw-1, Lvtw-1, apolipoprotein, apolipoproteins, MGC102525, Sep-1, Sep-2, Sep2, Human ApoA-1, ApoA-1, ApoA1, Apo A1, h-ApoA-1, rh-ApoA-1, recombinant human ApoA-1, ApoA1, recombinant ApoA-1, Apo, ApoA1, Apolipoprotein A-I, Apolipoprotein AI, Apolipoprotein |
| Gene Source | Human |
| Source | E. coli |
| Assay&Purity | SDS-PAGE; ≥97% |
| Assay2&Purity2 | HPLC; |
| Recombinant | Yes |
| Application Notes | Reconstitute in H₂O to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers and store at 4°C for 1 week or –20°C for future use. |
| Format | Lyophilized protein |
| Storage | -20°C; Sterile filtered and lyophilized with no additives |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
ApoA-I is a 29.0 kDa protein produced in the liver and intestine, and secreted as the predominant constituent of nascent high-density lipoprotein (HDL) particle. ApoA-I, which is found exclusively in HDL, has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is though to inhibit atherogenesis. For this reason HDL is also known as the “good cholesterol.” The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic Vascular diseases. Recombinant human ApoA-I is a 28.2 kDa protein of 244 amino acid residues.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.

